E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
The term obese describes a person who's very overweight. For the trial we will look at patients with poor weight loss after surgery and with suboptimal blood level of glucagon-like peptide-1 (GLP-1). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10068900 |
E.1.2 | Term | Bariatric surgery |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029883 |
E.1.2 | Term | Obesity |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to compare the efficacy of 24 weeks of subcutaneous liraglutide 3.0 mg versus placebo administration, as an adjunct to diet and exercise, on %WL in participants with poor weight-loss and a sub-optimal active GLP-1 response following primary RYGB or SG at the end of the 24-week treatment period. |
|
E.2.2 | Secondary objectives of the trial |
To compare the effect of 24-week subcutaneous liraglutide 3.0 mg versus placebo administration as an adjunct to diet and exercise in participants with poor weight-loss and a sub-optimal active GLP-1 response following primary RYGB or SG, at the end of the 24-week treatment period, upon: 1. Change in fat, lean body mass and bone density. 2. Change in circulating fasted glucose, insulin, HbA1c and leptin, and meal-stimulated glycaemic index, gut hormones and appetite response. 3. Change in HRQoL measures. 4. Change in physical functional assessments and activity levels. 5. Change in healthcare service usage. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients, 1 year or more after primary RYGB or primary SG, with poor weight-loss (<20% WL) that is not caused by either a surgical or psychological problem. 2. Adults, 18-64 years inclusive. 3. Suboptimal nutrient-stimulated GLP-1 response assessed by a meal test. Suboptimal active GLP-1 response is defined as a ≤2-fold increase in active GLP-1 circulating levels between time 0 and time 30 minutes. 4. Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control, abstinence) from the time consent is signed until 6 weeks after treatment discontinuation. 5. Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for trial treatment. NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (i.e. they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. 6. ≤5 % variation in body weight over preceding 3 months. 7. Fluent in English and able to understand and complete questionnaires. 8. Willing and able to provide written informed consent and comply with the trial protocol.
|
|
E.4 | Principal exclusion criteria |
1. Had a surgical procedure other than gastric bypass and sleeve gastrectomy,or revision bariatric surgery of any operation type. 2. Pregnant or lactating mothers. 3. Participation in other clinical intervention trial. 4. Lifetime history of suicidal behaviour or severe depression assessed by direct questioning. 5. Clinically significant medical abnormalities (e.g., unstable hypertension, clinically significant ECG abnormalities, liver cirrhosis, AST or ALT > 3x the upper normal limit). 6. Heart rate ≥ 100 beats/minute at screening on two separate measurements. 7. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg). 8. Renal impairment (estimated glomerular infiltration rate (eGFR <30 ml/min 1.73 m2) 9. Known or suspected hypersensitivity to liraglutide 3.0 mg and placebo or any of the excipients involved in their formulation. 10. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. 11. Personal history of pancreatitis. 12. Uncontrolled hypothyroidism or hyperthyroidism. 13. History of stroke, unstable angina, acute coronary syndrome, congestive heart failure New York Heart Association class III-IV within the preceding 12 months. 14. History of arrhythmias. 15. Inflammatory bowel disease. 16. Diabetic gastroparesis. 17. Concomitant GLP-1 receptor agonist usage. 18. Concomitant usage of medications that cause weight gain or weight loss. 19. Concomitant usage of DPPIV-inhibitors. 20. Insulin usage. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome of this trial is %WL from the baseline visit to the end of treatment visit at 24 weeks. Percentage weight loss will be calculated using the following formula: %WL = [(weight at the baseline visit – weight at the end of the 24-week treatment period)/ weight at the baseline visit] x 100, measured at the end of trial. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
There will be a single timepoint for the evaluation of the primary outcome corresponding to the end of treatment, i.e. week 24. |
|
E.5.2 | Secondary end point(s) |
The secondary outcomes of this trial are: 1. To compare changes in fat (%), lean body mass (%) and bone density from baseline visit to end of 24-week treatment period, assessed using DXA scanning, between liraglutide 3.0 mg and placebo. 2. To compare changes in circulating fasted glucose, insulin, HbA1c and leptin, and meal-stimulated glycaemic index, gut hormones and appetite response from baseline visit to end of 24-week treatment period between liraglutide 3.0 mg and placebo. 3. To compare changes in HRQoL (aggregate scores) assessed using adapted CSRI, EQ-5D-3L, IWQOL-Lite and BDI from baseline visit to end of 24-week treatment period between liraglutide 3.0 mg and placebo. 4. To compare changes in characteristics of attitude and symptom of depression (aggregate scores) assessed using BDI from baseline visit to end of 24-week treatment period between liraglutide 3.0 mg and placebo. 5. To compare changes in physical fitness assessed using 6MWT (distance covered in m2), STS test (s) and handgrip test (kg) from baseline visit to end of 24-week treatment period between liraglutide 3.0 mg and placebo
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
All of the above will be evaluated at baseline, at 4 follow-up visits (weeks 2, 4, 8 and 17) and at the end of treatment visit (week 24) for each participant. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of trial is the last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 30 |